Novo Holdings, RA Capital Management, Royalty Pharma, SR One, and TPG Life Sciences Innovations led a $112.25m Series C round in Elektrofi.

Investment firms Novo Holdings, RA Capital Management, Royalty Pharma, SR One, and TPG Life Sciences Innovations led a $112.25m Series C round in Elektrofi, a biopharmaceutical delivery technology company focused on improving the patient experience and expanding access to life-changing medicines. "At Elektrofi, we envision a world in which patients have the independence they need – around how and where they take their medications – to live life on their terms. The industry is on the cusp of a drug delivery revolution, and Elektrofi is proud to be leading it with Hypercon™, a broadly applicable platform for the hyper concentration and stabilization of biopharmaceuticals. With our team of industry experts, distinguished Board Directors, world-class investors, and pharma partners, we look forward to scaling our proprietary technology in the interest of bringing life-changing medicines to patients across the globe as quickly as possible," Chase Coffman, Elektrofi CEO.